The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Alzheimer's & Dementia - Tập 7 - Trang 270-279 - 2011
Marilyn S. Albert1, Steven T. DeKosky2,3, Dennis Dickson4, Bruno Dubois5, Howard H. Feldman6, Nick C. Fox7, Anthony Gamst8, David M. Holtzman9,10, William J. Jagust11, Ronald C. Petersen12, Peter J. Snyder13,14, Maria C. Carrillo15, Bill Thies15, Creighton H. Phelps16
1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
2Office of the Dean, University of Virginia, Charlottesville, VA, USA
3Department of Neurology, University of Virginia, Charlottesville, VA, USA
4Department of Pathology, Mayo Clinic, Jacksonville, FL, USA
5Institute for Memory and Alzheimer’s Disease, INSERM Unit Cognition, Neuro-imagerie et maladies due Cerveau, Groupe Hospitalier Pitie-Salpetriere, Paris, France
6Bristol-Myers Squibb Neuroscience, Wallingford, CT, USA
7Institute of Neurology, University College London, London, United Kingdom
8Department of Neuroscience, University of California, San Diego, CA USA
9Department of Neurology, Washington University, St. Louis, MO, USA
10Knight Alzheimer's Disease Research Center, Washington University, St. Louis, MO, USA
11Helen Wills Neuroscience Institute, University of California, Berkeley, CA USA
12Department of Neurology, Mayo Clinic, Rochester, MN, USA
13Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, USA
14Department of Neurology Alpert Medical School of Brown University Providence RI USA
15Alzheimer's Association Chicago IL USA
16National Institute on Aging, Bethesda, MD, USA

Tóm tắt

The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis, and (2) research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings.


Tài liệu tham khảo

10.1016/j.jalz.2011.03.004 10.1016/j.jalz.2011.03.005 10.1016/j.jalz.2011.03.003 10.1097/01.JGP.0000221334.65330.55 10.1001/archneur.56.3.303 10.1111/j.1365-2796.2004.01388.x 10.1016/S1474-4422(07)70178-3 10.1212/01.WNL.0000152982.47274.9E 10.1001/archneur.63.1.38 10.1001/archneur.63.5.665 10.1111/j.1365-2796.2004.01380.x Schellenberg G, 2006, Early Alzheimer's disease genetics, J Alzheimers Dis, 9, 367, 10.3233/JAD-2006-9S341 Bertram L, 2010, The genetics of Alzheimer disease: back to the future, Neuron, 21, 270, 10.1016/j.neuron.2010.10.013 10.1001/archneur.62.2.192 10.1016/S1474-4422(03)00530-1 10.1002/ana.21610 10.1002/ana.20730 10.1097/00002093-200307000-00010 10.1016/S1052-5149(03)00025-X 10.1016/j.jalz.2005.11.002 10.1093/brain/awm336 10.1038/nrd3115
Thông tin
Thông tin xuất bản

Alzheimer's & Dementia

Tập 7

270-279

Thông tin tác giả